Compugen Net Income
| CGEN Stock | USD 1.76 0.05 2.92% |
As of the 10th of February, Compugen shows the Risk Adjusted Performance of 0.0417, mean deviation of 2.92, and Downside Deviation of 3.54. Compugen technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Compugen Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 10.5058 | Revenue | Earnings Share (0.30) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -12.8 M | -13.4 M | |
| Net Loss | -12.8 M | -13.4 M | |
| Net Loss | -30.3 M | -31.8 M | |
| Net Loss | (0.14) | (0.15) | |
| Net Income Per E B T | 1.32 | 0.82 |
Compugen | Net Income | Build AI portfolio with Compugen Stock |
Evaluating Compugen's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Compugen's fundamental strength.
Latest Compugen's Net Income Growth Pattern
Below is the plot of the Net Income of Compugen over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Compugen financial statement analysis. It represents the amount of money remaining after all of Compugen operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Compugen's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Compugen's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (14.23 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Compugen Net Income Regression Statistics
| Arithmetic Mean | (20,628,070) | |
| Coefficient Of Variation | (44.90) | |
| Mean Deviation | 7,992,766 | |
| Median | (18,754,000) | |
| Standard Deviation | 9,262,702 | |
| Sample Variance | 85.8T | |
| Range | 28.9M | |
| R-Value | (0.25) | |
| Mean Square Error | 85.9T | |
| R-Squared | 0.06 | |
| Significance | 0.34 | |
| Slope | (454,568) | |
| Total Sum of Squares | 1372.8T |
Compugen Net Income History
Other Fundumenentals of Compugen
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Compugen Net Income component correlations
Compugen Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Compugen is extremely important. It helps to project a fair market value of Compugen Stock properly, considering its historical fundamentals such as Net Income. Since Compugen's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Compugen's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Compugen's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Life Sciences Tools & Services sector continue expanding? Could Compugen diversify its offerings? Factors like these will boost the valuation of Compugen. Projected growth potential of Compugen fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Compugen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.30) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
Investors evaluate Compugen using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Compugen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Compugen's market price to deviate significantly from intrinsic value.
It's important to distinguish between Compugen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Compugen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Compugen's market price signifies the transaction level at which participants voluntarily complete trades.
Compugen 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Compugen's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Compugen.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Compugen on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Compugen or generate 0.0% return on investment in Compugen over 90 days. Compugen is related to or competes with Innate Pharma, Nuvectis Pharma, Molecular Partners, Milestone Pharmaceuticals, Rani Therapeutics, Cybin, and Cardiff Oncology. Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes ... More
Compugen Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Compugen's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Compugen upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.54 | |||
| Information Ratio | 0.0181 | |||
| Maximum Drawdown | 23.25 | |||
| Value At Risk | (5.00) | |||
| Potential Upside | 6.57 |
Compugen Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Compugen's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Compugen's standard deviation. In reality, there are many statistical measures that can use Compugen historical prices to predict the future Compugen's volatility.| Risk Adjusted Performance | 0.0417 | |||
| Jensen Alpha | 0.0717 | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | 0.021 | |||
| Treynor Ratio | 0.1579 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Compugen's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Compugen February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0417 | |||
| Market Risk Adjusted Performance | 0.1679 | |||
| Mean Deviation | 2.92 | |||
| Semi Deviation | 3.21 | |||
| Downside Deviation | 3.54 | |||
| Coefficient Of Variation | 2384.08 | |||
| Standard Deviation | 4.12 | |||
| Variance | 16.95 | |||
| Information Ratio | 0.0181 | |||
| Jensen Alpha | 0.0717 | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | 0.021 | |||
| Treynor Ratio | 0.1579 | |||
| Maximum Drawdown | 23.25 | |||
| Value At Risk | (5.00) | |||
| Potential Upside | 6.57 | |||
| Downside Variance | 12.5 | |||
| Semi Variance | 10.3 | |||
| Expected Short fall | (3.62) | |||
| Skewness | 1.03 | |||
| Kurtosis | 2.52 |
Compugen Backtested Returns
As of now, Compugen Stock is very risky. Compugen secures Sharpe Ratio (or Efficiency) of 0.0383, which signifies that the company had a 0.0383 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Compugen, which you can use to evaluate the volatility of the firm. Please confirm Compugen's Mean Deviation of 2.92, downside deviation of 3.54, and Risk Adjusted Performance of 0.0417 to double-check if the risk estimate we provide is consistent with the expected return of 0.16%. Compugen has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.03, which signifies a somewhat significant risk relative to the market. Compugen returns are very sensitive to returns on the market. As the market goes up or down, Compugen is expected to follow. Compugen right now shows a risk of 4.25%. Please confirm Compugen total risk alpha, expected short fall, price action indicator, as well as the relationship between the value at risk and daily balance of power , to decide if Compugen will be following its price patterns.
Auto-correlation | -0.27 |
Weak reverse predictability
Compugen has weak reverse predictability. Overlapping area represents the amount of predictability between Compugen time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Compugen price movement. The serial correlation of -0.27 indicates that nearly 27.0% of current Compugen price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.27 | |
| Spearman Rank Test | 0.11 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Compugen Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Compugen reported net income of (14.23 Million). This is 104.17% lower than that of the Life Sciences Tools & Services sector and 120.32% lower than that of the Health Care industry. The net income for all United States stocks is 102.49% higher than that of the company.
Compugen Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Compugen's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Compugen could also be used in its relative valuation, which is a method of valuing Compugen by comparing valuation metrics of similar companies.Compugen is currently under evaluation in net income category among its peers.
Compugen Current Valuation Drivers
We derive many important indicators used in calculating different scores of Compugen from analyzing Compugen's financial statements. These drivers represent accounts that assess Compugen's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Compugen's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 963.8M | 362.1M | 61.9M | 137.0M | 123.3M | 164.4M | |
| Enterprise Value | 959.9M | 357.0M | 52.8M | 121.7M | 109.5M | 146.1M |
Compugen Fundamentals
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (4.17) % | ||||
| Current Valuation | 72.52 M | ||||
| Shares Outstanding | 93.54 M | ||||
| Shares Owned By Insiders | 2.02 % | ||||
| Shares Owned By Institutions | 13.52 % | ||||
| Number Of Shares Shorted | 1.14 M | ||||
| Price To Earning | (4.86) X | ||||
| Price To Book | 3.65 X | ||||
| Price To Sales | 23.32 X | ||||
| Revenue | 27.86 M | ||||
| Gross Profit | 513 K | ||||
| EBITDA | (14.4 M) | ||||
| Net Income | (14.23 M) | ||||
| Cash And Equivalents | 88.21 M | ||||
| Cash Per Share | 1.02 X | ||||
| Total Debt | 2.91 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | 49.6 M | ||||
| Short Ratio | 1.81 X | ||||
| Earnings Per Share | (0.30) X | ||||
| Target Price | 5.8 | ||||
| Number Of Employees | 74 | ||||
| Beta | 2.91 | ||||
| Market Capitalization | 160.97 M | ||||
| Total Asset | 115 M | ||||
| Retained Earnings | (488.76 M) | ||||
| Working Capital | 85.84 M | ||||
| Current Asset | 53.09 M | ||||
| Current Liabilities | 8.38 M | ||||
| Net Asset | 115 M |
About Compugen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Compugen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Compugen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Compugen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Compugen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Compugen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compugen will appreciate offsetting losses from the drop in the long position's value.Moving against Compugen Stock
The ability to find closely correlated positions to Compugen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Compugen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Compugen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Compugen to buy it.
The correlation of Compugen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Compugen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Compugen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Compugen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Life Sciences Tools & Services sector continue expanding? Could Compugen diversify its offerings? Factors like these will boost the valuation of Compugen. Projected growth potential of Compugen fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Compugen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.30) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
Investors evaluate Compugen using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Compugen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Compugen's market price to deviate significantly from intrinsic value.
It's important to distinguish between Compugen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Compugen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Compugen's market price signifies the transaction level at which participants voluntarily complete trades.